Medication Deserts: Geographic Inequity in Pharmaceutical Access and Its Toll on Chronic Disease Outcomes

A Quiet Crisis in the Drug Store Aisle

For most Americans with employer-sponsored insurance and reliable transportation, filling a prescription is a minor inconvenience—a brief detour on the way home from a clinic visit. For millions of others, it is a logistical and financial ordeal that frequently ends in a medication going unfilled. The consequences of that unfilled prescription—a missed antihypertensive, a delayed insulin refill, an antidepressant that runs out before the next paycheck—accumulate quietly in emergency department admission records, in hemoglobin A1c values, and in the actuarial tables of premature mortality.

The emerging body of research on pharmaceutical access inequity makes a compelling and troubling case: the geography of medication availability in the United States is not random. It tracks, with uncomfortable precision, the geography of race and income. Neighborhoods where residents are predominantly Black, Hispanic, or low-income are significantly more likely to be situated in areas researchers have begun calling medication deserts—communities where pharmacy density is insufficient to meet population need, where remaining pharmacies carry limited formularies, and where the structural conditions of pharmaceutical distribution systematically prioritize more profitable markets.

Mapping the Pharmacy Closure Wave

Over the past fifteen years, the United States has experienced a substantial contraction in its retail pharmacy infrastructure. National chain pharmacies, facing margin pressures from pharmacy benefit managers and the migration of high-volume generic dispensing to mail-order platforms, have closed thousands of locations, with closures concentrated disproportionately in urban neighborhoods with high proportions of Medicaid and uninsured patients and in rural communities where population density makes sustained profitability difficult.

Research published in Health Affairs and JAMA Network Open has documented this geographic patterning in granular detail. Studies examining pharmacy density at the census tract level have consistently found that predominantly Black and Hispanic neighborhoods in major metropolitan areas have significantly fewer pharmacies per capita than predominantly white neighborhoods, even after controlling for population density. In some urban markets, the disparity in pharmacy accessibility between high- and low-income census tracts exceeds a factor of three.

Independent pharmacies, which have historically served as the primary pharmaceutical access point in many underserved communities, have been particularly vulnerable. Unable to negotiate the reimbursement rates available to large chains and squeezed by direct and indirect remuneration fees imposed by pharmacy benefit managers, independent pharmacies in low-income neighborhoods have closed at rates that outpace national averages. Each closure removes not only a dispensing location but also a trusted community health resource—a pharmacist who knew patients by name, who counseled on drug interactions in Spanish or Haitian Creole, and who extended informal credit to patients who came up short at the counter.

Supply Chain Prioritization and the Commercial Logic of Underservice

Beyond pharmacy closures, researchers and community health workers have identified a subtler dimension of pharmaceutical access inequity: the systematic underprioritization of certain medications in the supply chains serving lower-income markets. Specialty medications for complex chronic conditions, brand-name drugs that carry higher margins, and novel therapies are disproportionately available through pharmacies serving more affluent populations. Formulary limitations, stock-out frequencies, and the willingness of pharmacies to carry lower-margin generics vary in ways that disadvantage patients in lower-income areas.

Pharmacy researchers have documented this dynamic in the context of mental health medications, where studies have found that pharmacies in predominantly minority neighborhoods are significantly less likely to stock certain atypical antipsychotics and mood stabilizers than pharmacies in predominantly white neighborhoods. A landmark study published in Psychiatric Services found that in New York City, pharmacies in nonwhite neighborhoods were substantially less likely to carry adequate supplies of opioid use disorder medications, including buprenorphine—a finding with direct implications for treatment access in communities already bearing a disproportionate burden of substance use disorder.

For patients managing cardiovascular disease or type 2 diabetes, the consequences of supply chain inequity are measurable in clinical outcomes. Studies examining medication adherence in relation to pharmacy proximity have found that patients who must travel significant distances to access their prescriptions—or who encounter stock limitations when they arrive—demonstrate substantially lower rates of adherence to antihypertensive, statin, and antidiabetic regimens. The downstream effects on blood pressure control, glycemic management, and cardiovascular event rates are well-characterized in the epidemiological literature.

Insurance Gaps as a Compounding Variable

Pharmacy geography does not operate in isolation. For residents of medication deserts, access barriers are typically compounded by insurance coverage gaps that make the medications available at distant pharmacies financially inaccessible even when logistical barriers are overcome. Medicaid reimbursement rates, which vary substantially across states, influence which pharmacies are willing to accept Medicaid patients and which medications are covered without prior authorization requirements that impose additional administrative burdens on both patients and prescribers.

The expansion of Medicaid under the Affordable Care Act reduced some of these gaps, but significant coverage discontinuities remain, particularly in states that have not expanded Medicaid and in populations who cycle in and out of eligibility due to income volatility. Community health workers operating in these environments describe patients who have coverage when they receive a prescription but lose it before the next refill, creating interruptions in chronic disease management that can have serious clinical consequences.

Copayment assistance programs operated by pharmaceutical manufacturers provide some mitigation for commercially insured patients but are generally unavailable to Medicaid beneficiaries, creating a paradox in which the patients with the greatest financial barriers to medication access receive the least assistance from industry-sponsored programs.

Policy Responses and Research Priorities

The research community has proposed a range of interventions to address pharmaceutical access inequity, spanning regulatory, financial, and infrastructure domains. Proposals include the expansion of federally qualified health center pharmacies in underserved areas, reform of pharmacy benefit manager reimbursement practices to reduce the financial pressure driving independent pharmacy closures, and state-level policies that condition pharmaceutical distribution agreements on equitable geographic coverage requirements.

Some researchers have pointed to the potential of mobile pharmacy units and telepharmacy models to extend access in both rural and urban medication deserts, while acknowledging that these approaches address symptoms rather than underlying structural causes. Others have called for the incorporation of pharmacy access metrics into standard community health needs assessments conducted by hospitals and health systems, as a step toward making pharmaceutical access inequity visible in the planning and accountability frameworks that govern healthcare resource allocation.

What the evidence most compellingly demands, however, is recognition that medication deserts are not a natural feature of the healthcare landscape. They are the product of policy choices, market structures, and distributional priorities that can, with sufficient political will, be changed. For the millions of Americans managing serious chronic conditions in communities where the nearest pharmacy is a bus ride away and the formulary is incomplete when they arrive, that recognition is not an academic abstraction. It is a matter of daily survival.